Genomics Services Market Report 2026

The genomics services market size has grown rapidly in recent years. It will grow from $18.29 billion in 2025 to $21.56 billion in 2026 at a compound annual growth rate (CAGR) of 17.9%. The growth in the historic period can be attributed to early adoption by research institutes, sequencing service commercialization, growth of biopharma research, availability of skilled bioinformaticians, laboratory service expansion.

The genomics services market size is expected to see rapid growth in the next few years. It will grow to $37.78 billion in 2030 at a compound annual growth rate (CAGR) of 15%. The growth in the forecast period can be attributed to integration into routine clinical care, demand for preventive genomics, growth of companion diagnostics, digital health integration, expansion of genomics startups. Major trends in the forecast period include growing demand for sequencing and interpretation services, expansion of personalized genomic health services, increased outsourcing of genomic analysis, rising adoption of clinical genomics services, growth of population-scale genomics projects.

The rising demand for gene therapy is expected to drive the growth of the genomics services market in the coming years. Gene therapy is a medical approach that treats or prevents diseases by addressing the underlying genetic cause. It offers targeted treatments for genetic disorders and chronic diseases by correcting or modifying the responsible genes. Genomics services support gene therapy by enabling precise targeting of tissues, quantifying and characterizing viral vectors, and assessing the risk of vector shedding. For example, in April 2024, the U.S. Food and Drug Administration (FDA), a US-based government regulatory agency, reported that over 80% of rare diseases have a known genetic basis. To date, the FDA has approved 22 gene therapy products, most of which target rare disorders. Consequently, the growing demand for gene therapy is fueling expansion in the genomics services market.

Key companies in the genomics services market are focusing on broadening their product offerings by incorporating advanced services such as long-read sequencing to meet the growing need for comprehensive genomic analysis and personalized medicine. Advanced long-read sequencing employs cutting-edge technologies to analyze DNA and RNA with longer sequence reads, enabling more complete and accurate characterization of genetic material. For instance, in April 2024, Clinical-Microbiomics A/S, a Denmark-based biotechnology company, introduced advanced long-read sequencing services, including 16S, ITS, 18S rRNA, isolate, and metagenomics sequencing. These services are designed to meet the demanding requirements of academic, clinical, and industrial research, delivering high-resolution insights and quality in microbial analysis. The expanded long-read sequencing capabilities, covering a wide array of sequencing options, aim to set new standards in microbiome research by providing detailed insights into microbial communities and supporting breakthrough discoveries.

In December 2023, The Bank of Nova Scotia, a Canada-based banking and financial services company, completed the acquisition of Bio-Rad Laboratories for an undisclosed sum. Through this acquisition, the Bank of Nova Scotia seeks to enhance its portfolio by leveraging Bio-Rad Laboratories’ expertise in genomics services. Bio-Rad Laboratories Inc. is a US-based company specializing in providing genomics services.

Major companies operating in the genomics services market are Thermo Fisher Scientific Inc., Danaher Corporation, Laboratory Corporation of America Holdings, Quest Diagnostics Incorporated, Eurofins Scientific SE, Agilent Technologies Inc., Illumina Inc., PerkinElmer Inc., QIAGEN Inc., LGC Limited, Myriad Genetics Inc., Q2 Solutions Inc., BGI Genomics Inc., 10x Genomics Inc., Invitae Corporation, Fulgent Genetics Inc., 23andMe Inc., Oxford Nanopore Technologies plc, Color Genomics Inc., GENEWIZ Inc., Foundation Medicine Inc., Pacific Biosciences Inc., Avance Biosciences Inc., Macrogen Inc.

North America was the largest region in the genomics services market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the genomics services market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the genomics services market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the genomics services market by increasing costs of imported sequencing consumables, laboratory equipment, and data analysis platforms. Service providers and research institutions are most affected due to reliance on imported inputs. These tariffs raise service prices by increasing operational and infrastructure costs for sequencing and analysis workflows, affecting client affordability. However, they encourage local service capability development, promoting regionally based sequencing facilities and data analytics expertise.

The genomics services market research report is one of a series of new reports that provides genomics services market statistics, including genomics services industry global market size, regional shares, competitors with a genomics services market share, detailed genomics services market segments, market trends and opportunities, and any further data you may need to thrive in the genomics services industry. This genomics services market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Genomics services focus on analyzing an individual’s genetic material to provide insights into their health, ancestry, and potential risk for diseases. These services often employ advanced technologies, such as deoxyribonucleic acid (DNA) sequencing, to decode a person’s genome and deliver personalized recommendations for healthcare and lifestyle decisions based on genetic information.

The primary products in genomics services include instruments or systems or software, and consumables and reagents. Instruments are devices or tools designed for specific scientific or technical tasks, while systems are sets of interconnected components that work together to perform a particular function. Software consists of programs and instructions that enable computers and electronic devices to execute tasks, process data, or manage operations. The range of services includes gene expression analysis (RNA-Seq), epigenomics services, genotyping, next-generation sequencing, Sanger sequencing, and others. These services are utilized by various end users, including research institutes, healthcare facilities and diagnostic centers, pharmaceutical and biotechnology companies, and contract research organizations (CROs).

The genomics services market consists of revenues earned by entities by providing services such as experimental design consultation, library preparation, sequencing services, and data analysis. The market value includes the value of related goods sold by the service provider or included within the service offering. The genomics services market also includes sales of DNA sequencing kits, DNA sequencing platforms, bioinformatics tools, and sequencing platforms. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.